Lead IASO Bio’s international commercialization across SEA, Oceania, Central and North Asia, the Middle East, North Africa and Türkiye (MENAT), and Latin America. Act as Principal for IASO Bio’s acquisition of Medisix, a Singapore-based CAR-T company.

Brian Yang serves as Chief Business Officer for CMS R&D and Rxilient. Prior to joining CMS group. Most recently, Brian was Head of Business Development APAC at Everest Medicine. Prior to Everest, he served as Vice President, head of strategy and business development at ArkBio. Prior to ArkBio, he served as Head of business development at Terns Pharmaceuticals (Nasdaq: TERN). Before that he held various positions in financial advisory, investor relations, business development, consulting at Rayo Advisors, TPP Healthcare, Amgen, Yifan Pharma, and Gloria Pharma.

Dr. Changjin Huang is an Associate Professor in School of Mechanical and Aerospace Engineering (MAE) at Nanyang Technological University (NTU). He received his bachelor’s degree from University of Science and Technology of China (USTC) and Ph.D. degree from Pennsylvania State University. Before joining NTU in 2018, he was a postdoctoral fellow in Department of Mechanical Engineering at Northwestern University from 2014-2015 and in Department of Biomedical Engineering at Carnegie Mellon University (CMU) from 2016-2018. Dr. Huang’s research focuses on mechanics and manufacturing of soft and living systems. He has published over 70 peer-reviewed articles in international journals. Dr. Huang is an Associate Editor of Journal of Micromechanics and Molecular Physics (JMMP), Associate Editor of Journal of Polymer Materials (JPM), and Editorial Board member of npj Soft Matter.

Mr New Soon Tee is Chief Executive Officer of Pick Network Pte Ltd, the IMDA subsidiary that operates Singapore's Nationwide Parcel Locker Network as a neutral platform open to every logistics service provider. A thirty-year veteran of the logistics, ICT and manufacturing industries, he was previously Cluster Director for Trade & Connectivity at IMDA, where he led the Locker Alliance pilot — 70 locker stations serving 80,000 households — alongside autonomous delivery trials and the inception of TradeTrust to digitalise international trade. He earlier held senior IT leadership roles at General Electric, Sembcorp Logistics, and Toll Global Logistics. He now oversees Pick's medication delivery trial with Singapore's public healthcare institutions, the first at-scale application of locker collection to prescription medication under SS 644.

Syafikah Huda Paiman is a Research Fellow at the School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, Singapore. She holds a PhD in Chemical Engineering and has multidisciplinary expertise in plastic-waste upcycling, membrane separation, advanced materials, photocatalysis, and antimicrobial technologies. Her current research focuses on developing sustainable processes that convert plastic waste into high-value chemicals, alongside downstream separation and product-recovery strategies. She also contributes to PURE—Plastics Upcycling using Renewable Energy—a technology platform designed to transform plastic waste into valuable chemical feedstocks through integrated mechanochemical and electrochemical processes. Before joining NTU, she worked in industrial product development, where she led the formulation and commercial application of antimicrobial additives for polymers, packaging, water pipes, and consumer products. Her experience spans research translation, regulatory compliance, customer-focused technology development, and manufacturing scale-up.

A/Prof Timothy Tan’s (School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University Singapore) research interest is in RNA therapeutics and oligonucleotides manufacturing. He has published more than 150 peer-reviewed papers in international journals and obtained/applied > 10 patents. He was awarded Singapore President’s Public Administration Award 2015 and Young Investigator Award in “International Symposium of Materials on Regenerative Medicine 2012”.

A/Prof Timothy has ventured into a RNA start-up, RNAscence Biotechnology, which he co-founded and co-invented the world’s first transdermal siRNA gene silencing technology.